Search results
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
Fox News· 6 days agoA combination COVID-influenza vaccine is apparently one step closer to hitting the market. Moderna,...
2-in-1 shot for flu and COVID shows promise in advanced trial
Live Science via Yahoo News· 6 days agoModerna representatives told news outlets that the company aspires to have the new shot approved by...
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
Zacks via Yahoo Finance· 5 days agoData from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination...
Moderna Falls, Though Says Covid/Flu Shot Topped Rivals
Investor's Business Daily· 6 days agoIn a study of about 8,000 people, Moderna's combination vaccine proved it's not inferior to the...
Moderna says its combination COVID and flu vaccine tested better than separate shots
CBS News· 6 days agoModerna announced Monday that its combination COVID and flu vaccine showed positive results in a...
National Academies Issue New Broad Definition of Long COVID
Medscape· 6 days agoA new broadly inclusive definition of long COVID from the National Academies of Sciences,...
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks· 2 days agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Factbox-Layoffs pile up in US, Canada as companies uncertain of economy
MSN News· 3 days ago(Reuters) -Companies in the U.S. and Canada have continued their job cuts in 2024 after letting go...
Hospital-Acquired Infection Rates Remain High Post Pandemic
Medscape· 7 days agoA study across 120 US hospitals showed hospital-acquired gram-negative resistant infections were 13%...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 4 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...